These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 18279928

  • 1. Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.
    Cetnar JP, Malkowicz SB, Palmer SC, Wein AJ, Vaughn DJ.
    Urology; 2008 May; 71(5):942-6. PubMed ID: 18279928
    [Abstract] [Full Text] [Related]

  • 2. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E, Cancer Leukemia Group B.
    Cancer; 2008 Dec 01; 113(11):3137-45. PubMed ID: 18989865
    [Abstract] [Full Text] [Related]

  • 3. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
    Vaughn DJ, Brown AW, Harker WG, Huh S, Miller L, Rinaldi D, Kabbinavar F.
    Cancer; 2004 Feb 15; 100(4):746-50. PubMed ID: 14770430
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA, Greco FA, Morrissey LH, Raefsky EL, Steis RG, Butts JA, Hainsworth JD, Minnie Pearl Cancer Research Network.
    Cancer; 2003 Nov 15; 98(10):2192-8. PubMed ID: 14601089
    [Abstract] [Full Text] [Related]

  • 7. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
    Kelly WK, Zhu AX, Scher H, Curley T, Fallon M, Slovin S, Schwartz L, Larson S, Tong W, Hartley-Asp B, Pellizzoni C, Rocchetti M.
    Clin Cancer Res; 2003 Jun 15; 9(6):2098-107. PubMed ID: 12796374
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
    Shepard DR, Dreicer R, Garcia J, Elson P, Magi-Galluzzi C, Raghavan D, Stephenson AJ, Klein EA.
    J Urol; 2009 Apr 15; 181(4):1672-7; discussion 1677. PubMed ID: 19230915
    [Abstract] [Full Text] [Related]

  • 9. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
    Athanasiadis A, Tsavdaridis D, Rigatos SK, Athanasiadis I, Pergantas N, Stathopoulos GP.
    Anticancer Res; 2003 Apr 15; 23(3C):3085-8. PubMed ID: 12926166
    [Abstract] [Full Text] [Related]

  • 10. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
    Mackler NJ, Pienta KJ, Dunn RL, Cooney KA, Redman BG, Olson KB, Fardig JE, Smith DC.
    Clin Genitourin Cancer; 2007 Jun 15; 5(5):318-22. PubMed ID: 17645828
    [Abstract] [Full Text] [Related]

  • 11. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ, Hernandez-McClain J, Henary H.
    Am J Clin Oncol; 2008 Dec 15; 31(6):532-8. PubMed ID: 19060583
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
    Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA.
    Urol Oncol; 2011 Dec 15; 29(6):608-13. PubMed ID: 20022268
    [Abstract] [Full Text] [Related]

  • 13. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
    Beer TM, Lemmon D, Lowe BA, Henner WD.
    Cancer; 2003 Mar 01; 97(5):1217-24. PubMed ID: 12599228
    [Abstract] [Full Text] [Related]

  • 14. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE.
    J Natl Cancer Inst; 2007 Nov 07; 99(21):1613-22. PubMed ID: 17971530
    [Abstract] [Full Text] [Related]

  • 15. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
    Fornier MN, Seidman AD, Lake D, D'Andrea G, Bromberg J, Robson M, Van Poznak C, Panageas KS, Atienza M, Norton L, Hudis C.
    Clin Cancer Res; 2007 Jan 01; 13(1):223-7. PubMed ID: 17200358
    [Abstract] [Full Text] [Related]

  • 16. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N, Saito S, Ishidoya S, Ito A, Saito H, Kato M, Arai Y.
    Int J Urol; 2009 Sep 01; 16(9):733-8. PubMed ID: 19674167
    [Abstract] [Full Text] [Related]

  • 17. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K, Miura N, Azuma K, Karashima T, Kasahara K, Nakatsuzi H, Hashine K, Sumiyoshi Y.
    Hinyokika Kiyo; 2007 Feb 01; 53(2):99-104. PubMed ID: 17352158
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
    Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM.
    J Clin Oncol; 2006 Dec 01; 24(34):5408-13. PubMed ID: 17135641
    [Abstract] [Full Text] [Related]

  • 19. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
    Chiappino I, Destefanis P, Addeo A, Galetto A, Cucchiarale G, Munoz F, Zitella A, Ferrando U, Fontana D, Ricardi U, Tizzani A, Bertetto O.
    Am J Clin Oncol; 2007 Jun 01; 30(3):234-8. PubMed ID: 17551298
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project.
    Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A.
    Prostate; 1996 Jan 01; 28(1):51-7. PubMed ID: 8545281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.